BNTC

Benitec Biopharma Inc

Add to Watchlist

Advanced Chart

11.900

+0.1(0.847%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

11.980

Open

11.800

VWAP

11.76

Vol

33.38K

Mkt Cap

312.38M

Low

11.130

Amount

392.68K

EV/EBITDA(TTM)

Total Shares

9.37M

206.17M

EV/OCF(TTM)

P/S(TTM)

Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.

6 Analyst Rating

85.71% Upside

Wall Street analysts forecast BNTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTC is 22.10 USD with a low forecast of 12.50 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

85.71% Upside

Current: 11.900

Low

12.50

Averages

22.10

High

30.00

85.71% Upside

Current: 11.900

Low

12.50

Averages

22.10

High

30.00

TD Cowen

initiated

2025-07-07

Reason

TD Cowen

Price Target

2025-07-07

initiated

Reason

TD Cowen initiated coverage of Benitec Biopharma with a Buy rating and no price target. The company's DNA-directed 'silence and replace' platform combines RNAi silencing sequences with replacement genes, the analyst tells investors in a research note. The firm believes Benitec's lead asset BB-301 for oculopharyngeal muscular dystrophy showed "compelling" Phase 1/2 clinical data, with improving subjective and objective dysphagia measures in three patients.

JMP Securities

Silvan Tuerkcan

Buy

Maintains

$18 → $20

2025-04-10

Reason

JMP Securities

Silvan Tuerkcan

Price Target

$18 → $20

2025-04-10

Maintains

Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$28

2025-03-24

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$28

2025-03-24

Reiterates

Strong Buy

Reason

Citizens Capital Markets

Silvan Tuerkcan

Buy

Reiterates

$18

2025-03-18

Reason

Citizens Capital Markets

Silvan Tuerkcan

Price Target

$18

2025-03-18

Reiterates

Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$28

2025-02-21

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$28

2025-02-21

Reiterates

Strong Buy

Reason

Baird

Brian Skorney

Buy

Initiates

$30

2024-12-13

Reason

Baird

Brian Skorney

Price Target

$30

2024-12-13

Initiates

Buy

Reason

Baird initiated coverage of Benitec Biopharma with an Outperform rating and $30 price target. The firm says Benitec's BB-301 gene therapy packages siRNA and healthy protein into a one-time treatment of oculopharyngeal muscular dystrophy, a disease with high unmet need, no currently approved treatments, and no disease-modifying assets in the clinic other than BB-301. B-301 has greatly improved patients' ability to swallow with a clean safety profile to date, and the trial design provides a regular cadence of data updates over the next year, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Benitec Biopharma Inc (BNTC.O) is -7.19, compared to its 5-year average forward P/E of -2.42. For a more detailed relative valuation and DCF analysis to assess Benitec Biopharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.42

Current PE

-7.19

Overvalued PE

-0.09

Undervalued PE

-4.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.36

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.68

Undervalued EV/EBITDA

-1.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

166.61

Current PS

0.00

Overvalued PS

562.41

Undervalued PS

-229.20